Fig. S1. Effects of Smg7 ablation on cell death inducers.

(A) TNFα dose-response curves of Smg7 CRISPRi knockdown (Smg7 KD) compared to empty KD vector control NIH 3T3 cells (control KD). Viability data represent mean ± SEM of n = 4 technical replicates of two independent experiments.

(B) Viability of Smg7 -/- compared to parental MF cells (parental) against apoptosis inducers: 10 ng/mL tumor necrosis factor (TNFα), 100 ng/mL TNF-related apoptosis-inducing ligand (TRAIL), 12.5 ng/mL TNF-like weak inducer of apoptosis (TWEAK), 10 µg/mL lipopolysaccharide (LPS), co-treatment with 20 pg/mL cycloheximide (CHX) or 20 ng/mL interferon gamma (IFNγ).

(C) Viability of Smg7 -/- compared to parental MF cells (parental) against chemotherapeutic drugs: 20 µM Doxorubicin, 2 µM Staurosporine, 0.05 µM Vinblastine, 0.4 µM Paclitaxel, 250 mM Dichloroacetic acid, 50 µM 5-Fluorouracil. Viability data (B, C) are plotted as mean ± SEM of n = 3 or 4 technical replicates.